GTS Securities LLC Has $834,000 Stake in Hologic, Inc. (NASDAQ:HOLX)

GTS Securities LLC cut its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 46.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,564 shares of the medical equipment provider's stock after selling 9,912 shares during the period. GTS Securities LLC's holdings in Hologic were worth $834,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in HOLX. Barclays PLC increased its stake in shares of Hologic by 47.6% in the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock worth $58,507,000 after purchasing an additional 231,578 shares during the period. LaFleur & Godfrey LLC boosted its holdings in Hologic by 2.9% during the fourth quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider's stock valued at $9,399,000 after purchasing an additional 3,655 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Hologic by 44.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 63,744 shares of the medical equipment provider's stock worth $4,595,000 after acquiring an additional 19,688 shares in the last quarter. Sound Income Strategies LLC acquired a new position in shares of Hologic in the 4th quarter worth approximately $60,000. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of Hologic by 5.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 20,764 shares of the medical equipment provider's stock worth $1,497,000 after acquiring an additional 1,115 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Leerink Partners downgraded Hologic from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Leerink Partnrs cut shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Evercore ISI cut their price target on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Argus cut Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, Royal Bank of Canada reduced their price target on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Twelve analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Hologic presently has a consensus rating of "Hold" and a consensus target price of $77.42.

Insiders Place Their Bets

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of Hologic stock in a transaction on Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director now owns 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.88% of the company's stock.

Hologic Stock Performance

NASDAQ:HOLX traded down $0.61 on Friday, hitting $62.31. The company's stock had a trading volume of 870,419 shares, compared to its average volume of 2,249,027. The firm has a market capitalization of $13.89 billion, a P/E ratio of 19.65, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The stock has a fifty day moving average of $58.11 and a two-hundred day moving average of $66.10.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same quarter last year, the company earned $1.03 EPS. The company's revenue was down 1.2% on a year-over-year basis. Research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.